Compare Palantir Technologies Inc (PLTR) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs 22nd Century Group Inc — how do they compare? Palantir Technologies Inc trades at $208.49 (market cap $477.68B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Palantir Technologies Inc is far larger — about 768381.9× 22nd Century Group Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and 22nd Century Group Inc for 32 Days on average.
| PLTR | XXII | |
|---|---|---|
Market Cap | $477.68B | $621.67K |
Volume | 41,744,992 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $207.18 | $483.00 |
52-Week Low | $107.27 | $0.80 |
Typical Hold Time | 78 Days | 32 Days |
Enterprise Value | $468.48B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $205.71, up 6.01% with strong bullish momentum. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025 and net income margin expanding to 36.3%. Technical indicators signal bullish sentiment with the price approaching resistance at $206. Recent partnership with Armada for sovereign AI infrastructure and consistent earnings beats highlight the company's growth trajectory.
Palantir presents compelling growth prospects driven by AI platform adoption, though premium valuations (P/E 169.9, P/S 83.02) warrant caution. Analyst consensus remains positive with 54% buy ratings and $191.69 price target. Key risks include valuation sensitivity and competitive pressures in the AI software space. The company's strong cash flow generation and expanding commercial customer base support long-term upside potential.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
